SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000921895-21-000862
Filing Date
2021-03-26
Accepted
2021-03-26 16:46:59
Documents
5
Period of Report
2021-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8k12566003_03252021.htm 8-K 20792
2 ex101to8k12566003_03252021.htm EX-10.1 97734
3 ex102to8k12566003_03252021.htm EX-10.2 29986
4 ex991to8k12566003_03252021.htm EX-99.1 14253
5 GRAPHIC image_001.jpg GRAPHIC 8783
  Complete submission text file 0000921895-21-000862.txt   176478
Mailing Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 21778117
SIC: 2834 Pharmaceutical Preparations